Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Abstract

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis (IPF), but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. Objectives: To investigate safety, tolerability, and pharmacokinetic and exploratory efficacy endpoints in patients treated with nintedanib and add-on pirfenidone versus nintedanib alone. Methods: Patients with IPF and FVC greater than or equal to 50% predicted at screening who completed a 4- to 5-week run-in with nintedanib 150 mg twice daily without dose reduction or treatment interruption were randomized to receive nintedanib 150 mg twice daily with add-on pirfenidone (titrated to 801 mg three times daily) or nintedanib 150 mg twice daily alone in an open-label manner for 12 weeks. The primary endpoint was the percentage of patients with on-treatment gastrointestinal adverse events from baseline to Week 12. Analyses were descriptive and exploratory. Measurements and Main Results: On-treatment gastrointestinal adverse events were reported in 37 of 53 patients (69.8%) treated with nintedanib with add-on pirfenidone and 27 of 51 patients (52.9%) treated with nintedanib alone. Predose plasma trough concentrations of nintedanib were similar when it was administered alone or with add-on pirfenidone. Mean (SE) changes from baseline in FVC at Week 12 were −13.3 (17.4) ml and −40.9 (31.4) ml in patients treated with nintedanib with add-on pirfenidone (n = 48) and nintedanib alone (n = 44), respectively. Conclusions: Nintedanib with add-on pirfenidone had a manageable safety and tolerability profile in patients with IPF, in line with the adverse event profiles of each drug. These data support further research into combination regimens in the treatment of IPF. Clinical trial registered with www.clinicaltrials.gov (NCT02579603).

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.201706-1301oc

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 11 references

Research works printed but not linked: 3

  1. Taniguchi, 2016, Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF [abstract], Eur Respir J, 48, PA2089
  2. Mason, 2017, Time-to-event analysis of common adverse events with pirfenidone in patients with IPF: a pooled analysis of three phase III clinical trials [abstract], Am J Respir Crit Care Med, 195, A6798
  3. Flaherty, 2017, Safety of the combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from an interim analysis after 12 weeks [astract], Am J Respir Crit Care Med, 195, A5398

Cited by

See all 306

Metadata

Authors
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., & Wuyts, W. A.
Affiliations
  • University of Catania (IT)
  • Heidelberg University (DE)
  • Università Cattolica del Sacro Cuore (IT)
  • University of British Columbia (CA)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • University Medical Center Utrecht (NL)
  • Boehringer Ingelheim (Germany) (DE)
  • Universitair Ziekenhuis Leuven (BE)
Corresponding author
Vancheri, Carlo
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2018-02-01
Volume
197
Issue
3
Pages
356-363
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2753035500
Cited by
305
References
11
Citations by year
2026: 26 · 2025: 29 · 2024: 38 · 2023: 37 · 2022: 34 · 2021: 36 · 2020: 32 · 2019: 43 · 2018: 27
FWCI
23.52
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, nintedanib, pirfenidone, combination therapy, adjunctive therapy, gastrointestinal adverse effects, safety and tolerability, pharmacokinetics, forced vital capacity, antifibrotic agents
MeSH terms
Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Indoles, Male, Middle Aged, Pyridones, Severity of Illness Index, Survival Rate, Treatment Outcome, Disease Progression, Risk Assessment, Idiopathic Pulmonary Fibrosis, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. https://app.cochat.ai/papers/10.1164/rccm.201706-1301oc
The paper
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., & Wuyts, W. A. (2018). Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201706-1301oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.